Simple DNA Test Could Identify the Risk of Inherited Diseases
|
By LabMedica International staff writers Posted on 04 Mar 2010 |
An inexpensive, fast, and accurate test using a drop of saliva pinpoints variations at critical points along the DNA chain.
Researchers from the University of Edinburgh (UK) developed the new method, which is based on dynamic chemical analysis, and delivers reliable results without the need for the expensive enzymes used in conventional DNA testing. The new method allows the analysis of single-nucleotide polymorphism, indel, and abasic sites using mass spectrometry as a readout tool. Differences or omissions in the DNA code could then show if someone is healthy, susceptible to disease, or is suffering from a serious medical condition.
Currently, the test can look for genetic variations for only one disease at a time, but the researchers hope the technique could be used eventually to decode the whole human genome, which would give information about genetic variations across the whole spectrum of disease. The test takes about 30 minutes, and the methodology is suitable for the dual analysis of heterozygous samples. The study describing the new technique was published in the February 2010 issue of the journal Angewandte Chemie.
"What we have developed is a way of testing chemically; that means not using enzymes, which are the current method,” said lead author Juan Diaz-Mochon, Ph.D., of the school of chemistry. "The technology offers a speedy, cost-efficient alternative to existing methods of DNA analysis.”
"The test could help spot diseases, such as pancreatic cancer, early. It could also indicate if someone had a risk of other diseases, such as heart problems or dementia,” added coauthor Prof. Mark Bradley, Ph.D. "We plan to test the technology further, extend our collaborations with leading researchers and companies in the DNA sequencing field, and establish our first commercial operations within the next six months.”
Related Links:
University of Edinburgh
Researchers from the University of Edinburgh (UK) developed the new method, which is based on dynamic chemical analysis, and delivers reliable results without the need for the expensive enzymes used in conventional DNA testing. The new method allows the analysis of single-nucleotide polymorphism, indel, and abasic sites using mass spectrometry as a readout tool. Differences or omissions in the DNA code could then show if someone is healthy, susceptible to disease, or is suffering from a serious medical condition.
Currently, the test can look for genetic variations for only one disease at a time, but the researchers hope the technique could be used eventually to decode the whole human genome, which would give information about genetic variations across the whole spectrum of disease. The test takes about 30 minutes, and the methodology is suitable for the dual analysis of heterozygous samples. The study describing the new technique was published in the February 2010 issue of the journal Angewandte Chemie.
"What we have developed is a way of testing chemically; that means not using enzymes, which are the current method,” said lead author Juan Diaz-Mochon, Ph.D., of the school of chemistry. "The technology offers a speedy, cost-efficient alternative to existing methods of DNA analysis.”
"The test could help spot diseases, such as pancreatic cancer, early. It could also indicate if someone had a risk of other diseases, such as heart problems or dementia,” added coauthor Prof. Mark Bradley, Ph.D. "We plan to test the technology further, extend our collaborations with leading researchers and companies in the DNA sequencing field, and establish our first commercial operations within the next six months.”
Related Links:
University of Edinburgh
Latest Molecular Diagnostics News
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
- Multi-Cancer Test Boosts Detection When Added to Standard Screening
- Blood-Based MRD Monitoring Supports Relapse Prevention in Leukemia
- Genomic Test Predicts Chemotherapy Benefit in Metastatic Prostate Cancer
- Blood Protein Markers Flag Multiple Sclerosis Risk Years Before Diagnosis
- Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
- Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
- Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
- Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








